8-KLeadership ChangesRegulation FDExhibits & Filings

CARDINAL HEALTH INC 8-K Report, Executive Changes (Sep 8, 2022)

Filed September 8, 2022For Securities:CAH

Summary

Cardinal Health Inc. (CAH) announced a significant leadership change within its Pharmaceutical Segment through an 8-K filing on September 8, 2022. Victor L. Crawford will be stepping down as Chief Executive Officer of the Pharmaceutical Segment, effective September 19, 2022. While he will remain with the company until November 13, 2022, to facilitate a smooth transition, his departure is being treated as an involuntary termination without cause under the Company's Senior Executive Severance Plan. This change is accompanied by broader organizational adjustments within the Pharmaceutical Segment, as detailed in a press release furnished with the filing. Investors should monitor the company's communication for further details on the replacement and the strategic implications of these changes for the Pharmaceutical Segment's future performance and direction. The severance package for Mr. Crawford is contingent upon the execution of a release and adherence to restrictive covenants.

Key Highlights

  • 1Victor L. Crawford is stepping down as CEO of the Pharmaceutical Segment, effective September 19, 2022.
  • 2Mr. Crawford will stay with Cardinal Health through November 13, 2022, to assist with the transition.
  • 3The company has determined Mr. Crawford's departure qualifies for severance benefits under the Senior Executive Severance Plan, classified as an involuntary termination without cause.
  • 4Receipt of severance benefits is subject to a general release and compliance with restrictive covenants.
  • 5The filing also announces broader organizational changes within the Pharmaceutical Segment.
  • 6A press release detailing these organizational changes is furnished as Exhibit 99.1.

Frequently Asked Questions

The filing states that Victor L. Crawford will cease to serve as Chief Executive Officer of the Pharmaceutical Segment. While the specific reasons for his departure are not detailed, the company has classified it as an involuntary termination without cause under its Senior Executive Severance Plan.

Mr. Crawford's role as CEO of the Pharmaceutical Segment officially ends on September 19, 2022. He will remain with Cardinal Health in a transitional capacity until November 13, 2022, to ensure a smooth handover.

Yes, the Board of Directors has determined that Mr. Crawford is entitled to severance benefits under the Cardinal Health, Inc. Senior Executive Severance Plan, as his departure is considered an involuntary termination without cause. However, the receipt of these benefits is conditional upon him executing a general release and complying with certain restrictive covenants.

Yes, the 8-K filing mentions that the company issued a news release announcing Pharmaceutical Segment organizational changes. Further details regarding these broader changes are available in the furnished press release (Exhibit 99.1).